Search

Duvelisib

[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

Porfimer sodium

It is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in

Polycarbophil

It is insoluble in water, dilute acids, and dilute alkali.

Brincidofovir

[A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections.

Tezacaftor

[L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.

Motexafin gadolinium

Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics.

Voretigene neparvovec

Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates. … [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095]

Exisulind

Rucaparib

Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.